In accordance with biochemical analyses, expression of hypertrophic marker Col10a1 and hypertrophic/osteogenic markers ALP and Runx2 were significantly up-regulated with BMP6 treatment relative to both OM and d0 levels at 4 and 6 weeks. The gene discussed is RUNX2; the disease is ocular melanoma.